Tango Therapeutics Stock Price, News & Analysis (NASDAQ:TNGX) $7.76 +0.16 (+2.11%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$7.44▼$7.8750-Day Range$6.52▼$12.0152-Week Range$2.47▼$13.03Volume452,879 shsAverage Volume625,197 shsMarket Capitalization$791.44 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Tango Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside106.2% Upside$16.00 Price TargetShort InterestBearish18.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$8.72 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.05) to ($1.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector629th out of 957 stocksPharmaceutical Preparations Industry298th out of 443 stocks 3.5 Analyst's Opinion Consensus RatingTango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, Tango Therapeutics has a forecasted upside of 106.2% from its current price of $7.76.Amount of Analyst CoverageTango Therapeutics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.39% of the float of Tango Therapeutics has been sold short.Short Interest Ratio / Days to CoverTango Therapeutics has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Tango Therapeutics has recently increased by 10.66%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTango Therapeutics does not currently pay a dividend.Dividend GrowthTango Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TNGX. Previous Next 2.4 News and Social Media Coverage News SentimentTango Therapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tango Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for TNGX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tango Therapeutics insiders have bought 382.51% more of their company's stock than they have sold. Specifically, they have bought $8,722,500.00 in company stock and sold $1,807,734.00 in company stock.Percentage Held by InsidersOnly 6.20% of the stock of Tango Therapeutics is held by insiders.Percentage Held by Institutions78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.05) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tango Therapeutics is -6.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tango Therapeutics is -6.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTango Therapeutics has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tango Therapeutics Stock (NASDAQ:TNGX)Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.Read More TNGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TNGX Stock News HeadlinesNovember 26, 2023 | americanbankingnews.comTango Therapeutics (NASDAQ:TNGX) Shares Down 3.6% November 13, 2023 | finance.yahoo.comHow Much Upside is Left in Tango Therapeutics, Inc. (TNGX)? Wall Street Analysts Think 115.31%December 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.November 13, 2023 | finance.yahoo.comTango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual MeetingNovember 10, 2023 | markets.businessinsider.comPositive Outlook for Tango Therapeutics: Comprehensive Analysis of Ongoing Clinical Trials and Promising PRMT5 InhibitorsNovember 10, 2023 | markets.businessinsider.comPositive Financial Performance and Promising Drug Development Bolster Tango Therapeutics’ Buy RatingNovember 9, 2023 | finance.yahoo.comNeed To Know: Analysts Are Much More Bullish On Tango Therapeutics, Inc. (NASDAQ:TNGX) RevenuesNovember 8, 2023 | finance.yahoo.comTango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business UpdatesDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 8, 2023 | benzinga.comTango Therapeutics: Q3 Earnings InsightsNovember 8, 2023 | finance.yahoo.comTango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNovember 7, 2023 | finance.yahoo.comTango Therapeutics to Present at the Jefferies London Healthcare ConferenceNovember 5, 2023 | morningstar.comTango Therapeutics Inc TNGXOctober 23, 2023 | seekingalpha.comCircling Bank On Tango TherapeuticsOctober 18, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Prophase Labs (PRPH), Tango Therapeutics (TNGX)October 17, 2023 | markets.businessinsider.comUnjustified Market Concerns over PRMT5 Efficacy and Potential of TNGX Shares: A Buy Rating AnalysisOctober 13, 2023 | msn.comTango Therapeutics stock plunges amid data release for Amgen PRMT5 drugOctober 13, 2023 | msn.comTango Therapeutics stock plunges amid Amgen PRMT5 drug data (update)October 9, 2023 | finance.yahoo.comWhat Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing'October 9, 2023 | msn.comWhy Shares of Tango Therapeutics Are Dropping MondaySeptember 18, 2023 | finance.yahoo.comTango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 14, 2023 | msn.comWhy Shares of Tango Therapeutics Climbed This WeekSeptember 6, 2023 | finance.yahoo.comTango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ CancersSeptember 5, 2023 | finance.yahoo.comTango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 2, 2023 | fool.comTango Therapeutics (NASDAQ: TNGX)August 31, 2023 | msn.comTango Therapeutics (TNGX) Price Target Increased by 10.75% to 17.17August 30, 2023 | finanznachrichten.deTango Therapeutics, Inc.: Tango Therapeutics Announces Updates to Its Board of DirectorsSee More Headlines Receive TNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2023Today12/03/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNGX CUSIPN/A CIK1819133 Webwww.tangotx.com Phone857-320-4900FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$16.00 Low Stock Price Target$16.00 Potential Upside/Downside+106.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,180,000.00 Net Margins-266.73% Pretax Margin-266.36% Return on Equity-41.41% Return on Assets-24.28% Debt Debt-to-Equity RatioN/A Current Ratio8.54 Quick Ratio8.54 Sales & Book Value Annual Sales$24.86 million Price / Sales31.84 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / Book2.86Miscellaneous Outstanding Shares101,990,000Free Float95,667,000Market Cap$791.44 million OptionableNot Optionable Beta0.86 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Barbara L. Weber M.D. (Age 66)President, CEO & Director Comp: $941.16kMs. Daniella Beckman CPA (Age 44)Chief Financial Officer Comp: $619.13kDr. Alan Ashworth FRS (Age 62)Ph.D., Founder & Member of Scientific Advisory Board Dr. Levi Garraway M.D. (Age 54)Ph.D., Founder Dr. William G. Kaelin Jr. (Age 65)M.D., Founder & Member of Scientific Advisory Board Dr. Timothy K. Lu M.D. (Age 42)Ph.D., Founder Dr. Antoni Ribas M.D. (Age 56)Ph.D., Founder & Member of Scientific Advisory Board Mr. Jannik N. Andersen Ph.D.Chief Scientific OfficerMr. Douglas J. Barry Esq. (Age 53)J.D., General Counsel, Chief Compliance Officer & Corporate Secretary Mr. John C. Ross M.S.Vice President of Human ResourcesMore ExecutivesKey CompetitorsVerve TherapeuticsNASDAQ:VERVPharming GroupNASDAQ:PHAROlema PharmaceuticalsNASDAQ:OLMAZentalis PharmaceuticalsNASDAQ:ZNTLNewAmsterdam PharmaNASDAQ:NAMSView All CompetitorsInsiders & InstitutionsWellington Management Group LLPBought 80,747 shares on 12/1/2023Ownership: 0.079%American Century Companies Inc.Bought 1,826 shares on 11/30/2023Ownership: 0.023%Jacobs Levy Equity Management Inc.Sold 175,295 shares on 11/17/2023Ownership: 0.141%Sei Investments Co.Bought 35,020 shares on 11/15/2023Ownership: 0.034%The Manufacturers Life Insurance Company Bought 18,080 shares on 11/15/2023Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions TNGX Stock Analysis - Frequently Asked Questions Should I buy or sell Tango Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNGX shares. View TNGX analyst ratings or view top-rated stocks. What is Tango Therapeutics' stock price target for 2024? 1 Wall Street research analysts have issued 1 year price objectives for Tango Therapeutics' shares. Their TNGX share price targets range from $16.00 to $16.00. On average, they anticipate the company's share price to reach $16.00 in the next year. This suggests a possible upside of 106.2% from the stock's current price. View analysts price targets for TNGX or view top-rated stocks among Wall Street analysts. How have TNGX shares performed in 2023? Tango Therapeutics' stock was trading at $7.25 on January 1st, 2023. Since then, TNGX shares have increased by 7.0% and is now trading at $7.76. View the best growth stocks for 2023 here. When is Tango Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024. View our TNGX earnings forecast. How were Tango Therapeutics' earnings last quarter? Tango Therapeutics, Inc. (NASDAQ:TNGX) posted its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.11. The firm earned $10.73 million during the quarter, compared to the consensus estimate of $8.05 million. Tango Therapeutics had a negative net margin of 266.73% and a negative trailing twelve-month return on equity of 41.41%. What ETF holds Tango Therapeutics' stock ? Range Cancer Therapeutics ETF holds 34,808 shares of TNGX stock, representing 1.18% of its portfolio. Who are Tango Therapeutics' major shareholders? Tango Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (11.42%), Adage Capital Partners GP L.L.C. (1.72%), Deerfield Management Company L.P. Series C (0.78%), Invesco Ltd. (0.76%), Northern Trust Corp (0.39%) and Charles Schwab Investment Management Inc. (0.36%). Insiders that own company stock include Adam Crystal and Boxer Capital, Llc. View institutional ownership trends. How do I buy shares of Tango Therapeutics? Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:TNGX) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.